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Abstract
Background: We previously reported infectious HCV clones that contain the convenient reporters, green fluorescent protein
(GFP) and Renilla luciferase (Rluc), in the NS5a-coding sequence. Although these viruses were useful in monitoring viral
proliferation and screening of anti-HCV drugs, the infectivity and yield of the viruses were low.
Methodology/Principal Findings: In order to obtain a highly efficient HCV cultivation system, we transfected Huh7.5.1 cells
[1] with JFH 5a-GFP RNA and then cultivated cells for 20 days. We found a highly infectious HCV clone containing two cell
culture-adapted mutations. Two cell culture-adapted mutations which were responsible for the increased viral infectivity
were located in E2 and p7 protein coding regions. The viral titer of the variant was ,100-fold higher than that of the
parental virus. The mutation in the E2 protein increased the viability of virus at 37uC by acquiring prolonged interaction
capability with a HCV receptor CD81. The wild-type and p7-mutated virus had a half-life of ,2.5 to 3 hours at 37uC. In
contrast, the half-life of viruses, which contained E2 mutation singly and combination with the p7 mutation, was 5 to
6 hours at 37uC. The mutation in the p7 protein, either singly or in combination with the E2 mutation, enhanced infectious
virus production about 10–50-fold by facilitating an early step of virion production.
Conclusion/Significance: The mutation in the E2 protein generated by the culture system increases virion viability at 37uC.
The adaptive mutation in the p7 protein facilitates an earlier stage of virus production, such as virus assembly and/or
morphogenesis. These reporter-containing HCV viruses harboring adaptive mutations are useful in investigations of the viral
life cycle and for developing anti-viral agents against HCV.
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Introduction
Over 180 million people worldwide are chronically infected
with hepatitis C virus (HCV), and are thus at high risk of
developing chronic liver diseases such as progressive hepatic
fibrosis, liver cirrhosis and hepatocellular carcinoma [2,3]. No
HCV vaccine is available to date, and there is no therapy that is
effective for all genotypes of HCV. Interferon-alpha (IFN-a)i n
combination with ribavirin is the only recommended therapy [4].
These treatments have a moderate response rate and are
associated with significant side effects [5,6].
HCV is a member of the Flaviviridae family of enveloped, positive-
strand RNA viruses [7]. The HCV genome consists of an
approximately 9.6-kb RNA molecule containing a large open
reading frame flanked by 59 and 39 non-translated regions (59 and
39NTRs). The viral proteins are translated as a single large
polyprotein of 3,010–3,040 amino acids, which is co- and/or post-
translationally processed by cellular and viral proteases into mature
structural (core, E1, E2) and nonstructural (p7, NS2, NS3, NS4a,
NS4b, NS5a, NS5b) viral proteins [8]. The envelope proteins, E1
and E2, are extensively glycosylated and form a non-covalent
complex that is believed to represent the building block for the viral
envelope [9,10]. P7 is a 63-amino-acid polypeptide that is often
incompletely cleaved from E2. It has two transmembrane domains
connected by a short hydrophilic segment [11]. The p7 protein
probably forms an ion channel involved in some step of virus
production [12]. In vivo experiments clearly indicate that p7 is
essential for infection, and two recent reports showed that p7 is
essential for production of infectious virions [13,14,15].
The availability of a cell culture system is a prerequisite for
studying the entire life cycle of a virus and to devise strategies for
prophylactic and therapeutic interventions [16]. The most recent
advance in this context is the development of a virus production
system based on the transfection of the human hepatoma cell line,
Huh7.5.1, with genomic HCV RNA (JFH1) isolated from a
patient with fulminant hepatitis [1,17,18,19].
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22808Figure 1. Generation of cell culture-adapted JFH 5a-GFP virus. (A) Cell-free culture supernatants were collected 6 days (JFH 5a-GFP pt6d) and
20 days (JFH 5a-GFP pt20d) after transfection, and used to inoculate Huh7.5.1 cells. HCV-infected cells were fixed 5 days after inoculation and then
treated with primary (anti-core monoclonal) and secondary (Alexa 555-conjugated donkey anti-mouse IgG) antibodies. The core-expressing cells are
shown in red and the Hoechst 33258-stained nuclei are shown in blue. (B) Schematic diagram of JFH 5a-GFP and its derivatives with a substituted
region (from Age I site to Avr II site) containing amplified DNA fragments from long distance RT-PCR of cell-adapted HCV RNA. (C) Huh7.5.1 cells
transfected with JFH 5a-GFP, Ad 9, Ad 12 or Ad 16 RNAs were grown on coverslips for 3 days and fixed. Core-expressing cells are shown in red as in
1A (panels d to f). The NS5a-GFP signal was visualized by fluorescence microscopy (green). The nuclei, shown in blue, were stained with Hoechst
A Cell Culture-Adapted Hepatitis C Virus
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e22808Previously, we reported infectious HCV clones that contain the
convenient reporters, green fluorescent protein (GFP) and Renilla
luciferase (Rluc), in the NS5a-coding sequence [20]. Although
these viruses were useful for monitoring the effects of antiviral
agents and for studying viral replication cycles, their infectivity was
too low for mass production of HCV virions. Here, we report cell
culture-adapted, reporter-containing HCV clones. A T563I
mutation in the E2 coding region increased the viability of
infectious virus in culture media at 37uC, and an N765D mutation
in the p7 protein increased virus production by augmenting an
early step of virion production. These cell culture-adapted
infectious viruses will facilitate HCV-related research, including
the development of anti-HCV drugs and vaccines.
Results
Generation of cell culture-adapted JFH 5a-GFP virus
As a first step to obtaining a highly efficient HCV cultivation
system, we transfected Huh7.5.1 cells with JFH 5a-GFP RNA [20]
and then cultivated cells for 20 days. Culture supernatants
harvested 6 and 20 days after transfection were used to inoculate
Huh7.5.1 cells, and the expression of core protein in infected cells
was examined by immunocytochemistry at 5 days post-infection.
As shown in Figure 1A, nearly 100% of cells from the media
obtained 20 days after transfection were infected. In contrast, only
a few cells from the media obtained 6 days after transfection were
infected. This difference in infectivity between 6-day and 20-day
post-transfection media could be an indication that infectious
virions containing adaptive mutations accumulated over time in
the media. This possibility was tested by isolating and analyzing
individual virus clones obtained from cells infected with the media
obtained 20 days after transfection. To identify cell culture-
adaptive mutations, we prepared total RNA from infected cells
and amplified the region encoding the core to NS2 by long
distance RT-PCR, as described in Materials and Methods
(Fig. 1B). After restriction enzyme digestion of PCR products
with AgeI and AvrII, this DNA fragment was inserted into the
parental JFH 5a-GFP construct (Fig. 1B). In vitro transcripts of 12
independent clones were prepared and transfected into Huh7.5.1
cells to investigate the expression of core and NS5a-GFP protein.
As shown in Figure 1C, three clones, designated Ad 9, Ad 12 and
Ad 16 expressed the core and NS5a-GFP protein. The remaining
nine clones did not express the core or NS5a-GFP protein. Cell
culture supernatants obtained 5 days after transfection with Ad 9,
Ad 12 and Ad 16 RNAs were examined for infectious virus
production by fluorescence microscopy and tested in a TCID50
assay. Huh7.5.1 cells inoculated with culture supernatants were
monitored by fluorescence microscope at 5 days post-infection
(Fig. 1D). Ad 9 and Ad 12 viruses showed higher infectivity
compared with the JFH 5a-GFP virus (panels a, b and c in Fig. 1D),
whereas cells inoculated with Ad 16 supernatant exhibited no
NS5a-GFP expression (panel d in Fig. 1D). The viral titers of Ad 9
and Ad 12, measured by a TCID50 assay, were 36-and 11-fold
higher, respectively, than parental JFH 5a-GFP (Fig. 1E). These
results suggest that adaptive mutations in Ad 9 and Ad 12
constructs increased virus infectivity. The absence of infectivity in
the Ad 16 construct, despite viral RNA replication and the
production of viral protein, is consistent with the presence of an
additional mutation in the Ad 16 construct that abolished virus
infectivity.
Mutations in E2 and p7 increase viral infectivity
To identify the mutations responsible for enhanced virus
infectivity, we sequenced the entire replaced regions of the Ad 9,
Ad 12 and Ad 16 constructs (Fig. 2). Five mutations were identified
in the Ad 9 construct, one of which was silent (CRT at nucleotide
position 3392). Four led to changes in amino acids: His 316 to Arg,
Thr 561 to Ile, Asn 765 to Asp, and Pro 1100 to Leu. Three and
eight mutations were identified in Ad 12 and Ad 16 constructs,
respectively. Interestingly, the N765D mutation (in p7) was
identified in all three constructs.
To determine which of these mutations was responsible for the
increased viral infectivity, we re-introduced the mutations
identified in the most efficient clone (Ad 9), alone and in
combination into the JFH 5a-GFP construct, to yield JFH-G m1
(mutation in E1 only), JFH-G m2 (mutation in E2 only), JFH-G
m3 (mutation in p7 only), JFH-G m4 (E2+p7 mutations) and JFH-
G m5 (NS2+NS3 mutations) (Fig. 3A). First, we compared viral
protein expression in cells transfected with the parental JFH 5a-
GFP with that in cells transfected with its derivatives containing
adaptive mutations (Fig. 3B). RNAs transcribed in vitro were
transfected into Huh7.5.1 cells by electroporation. Three days
after transfection, cell lysates were prepared and the levels of
NS5a-GFP and core protein were investigated by western blot
analysis using anti-NS5a and anti-core antibodies (Fig. 3B). Similar
levels of core and NS5a-GFP proteins were observed in cells
transfected with all RNAs. The infectivity of JFH 5a-GFP RNA
and its derivative RNAs (Ad 9, JFH-G m1, JFH-G m2, JFH-G m3,
JFH-G m4 and JFH-G m5) was monitored by inoculating
Huh7.5.1 cells with culture media from Huh7.5.1 cells transfected
with the corresponding RNAs and cultivated for 5 days. At 5 days
post-infection, NS5a-GFP fluorescence was observed by fluores-
cence microscopy (Fig. 3C). The combination of E2 and p7
mutations in JFH-G m4 increased viral infectivity (compare panels
f and a in Fig. 3C); none of the mutations in JFH-G m1 or JFH-G
m5 viruses had a significant effect (panels c and g in Fig. 3C).
Although the mutations in E2 and p7 proteins (T563I and N765D)
both increased virus infectivity, the patterns within infected cells
were different for each, with the E2 mutation (JFH-G m2)
exhibiting a dispersed intracellular distribution and p7 (JFH-G m3)
showing infection of cells at focal regions (compare panels d and e
in Fig. 3C).
An analysis of virus titer in culture supernatants yielded similar
results (Fig. 3D). The viral titer of the JFH-G m4 virus (containing
both mutations) was ,100-fold higher than that of the JFH 5a-GFP
virus (Fig. 3D), whereas that of JFH-G m2 and JFH-G m3
containing individual mutations in E2 and p7, respectively, each
increased by approximately 10-fold (Fig. 3D). The reporterless
viruses with the corresponding mutations showed similar virus
production to the mutant viruses with the reporter gene (Fig. S1). In
contrast, the titer of the JFH-G m1 virus was reduced about 50%
compared with that of JFH 5a-GFP virus, indicating that the
mutation in E1 protein (H316R) had a slightly negative effect on
virus infectivity (compare columns JFH-G m1 and JFH 5a-GFP in
Fig.3D). The lower infectivity of Ad 9 relative to JFH-G m4 may be
attributable to the opposing influence on infectivity caused by the
33258 (panels a to c). (D) Huh7.5.1 cells were infected with JFH 5a-GFP, Ad 9, Ad 12 or Ad 16 viruses. The NS5a-GFP signals were visualized by
fluorescence microscopy (green). (E) Virus titers were determined using a TCID50 assay. The bars and lines represent the means and standard
deviations, respectively, from three independent experiments.
doi:10.1371/journal.pone.0022808.g001
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andJFH-Gm4inFig.3D).ThemutationsinNS2 andNS3proteins
had no effect on viral infectivity (compare columns JFH-G m5 and
JFH 5a-GFP in Fig. 3D). Taken together, these results suggest that
two mutations, one in E2 and one in p7, enhance viral infectivity.
The E2 mutation increases virion viability and the p7
mutation augments virion assembly
Because it is easier to quantify luciferase activity than GFP signals,
we constructed JFH 5a-Rluc viruses containing either mutation (JFH-
R m2: E2 mutation; JFH-R m3: p7 mutation) and both mutations
(JFH-R m4) to elucidate the roles of adaptive mutations in E2 and p7
protein. Viral protein production reflecting RNA replication and
translation efficiencies of the adaptive mutants was determined by
measuring luciferase activity in transfected cells for 5 days (Fig. 4A).
Luciferase activity assays showed that there were no significant
differences in RNA replication or translation among cells transfected
for 120 hours with RNAs for JFH 5a-Rluc, JFH-R m2, JFH-R m3or
JFH-R m4 viruses (Fig. 4A). To determine the infectivity of these
viruses, we inoculated Huh7.5.1 cells with culture supernatants
obtained 5 days post-transfection and measured luciferase activity in
the cells. Consistently with the results obtained using JFH 5a-GFP
constructs of viruses with adaptive mutations (Fig. 3D), JFH 5a-Rluc
virus constructs containing individual mutations in E2 and p7 protein
each increased infectivity by ,10-fold, and the JFH-R m4 virus
containing both mutations showed the highest infectivity (Fig. 4B).
These results indicate that the two adaptive mutations are each
responsible for a similar increase the infectivity of JFH 5a-Rluc and
JFH 5a-GFP viruses.
To monitor viral release at various times after transfection, we
inoculated Huh7.5.1 cells with culture media harvested 24, 48, 72,
96 and 120 hours after transfecting with each RNA, and then
cultivated cells for 3 days. Luciferase activity in the HCV-infected
cells is shown in Figure 4C. The mutation in the p7 protein, either
singly or in combination with the E2 mutation, enhanced virus
release by ,10–50-fold (compare columns in Fig. 4C). This effect
was more pronounced at early time points (48 and 72 hours) than
at the last time point (120 hours). The mutation in the E2 protein
had a minor impact on the release of infectious virions (Fig. 4C).
To further investigate which step of virion production was
enhanced by the adaptive mutation in the p7 protein, we
compared the infectivity of intracellular virus to that of
extracellular virus. At 48 hours post-transfection, culture media
were harvested to collect the extracellular virus and cells were
washed and lysed by four freeze-thaw cycles to release intracellular
virus. Huh7.5.1 cells were infected with the cell lysates or culture
media, and then luciferase activity in the infected cells was
measured 3 days after infection. The infectivity of extracellular
virus (white column) and that of intracellular virus (gray column) is
shown in Figure 4D. The ratios of intracellular viruses to
extracellular viruses obtained from various mutants are shown in
Figure 4E. The number of infectious virions in both culture media
Figure 2. Genetic mutations identified in cell culture-adapted HCV RNAs. A schematic diagram of JFH 5a-GFP is shown at top. The positions
of predicted amino acid changes are depicted in bold characters, and those with silent mutations are depicted in plain characters.
doi:10.1371/journal.pone.0022808.g002
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e22808Figure 3. Mutations in E2 and p7 proteins increased viral infectivity. (A) Schematic diagram of JFH 5a-GFP and its derivatives containing
adaptive mutations. Mutations are indicated with an asterisk; dedicated names are on the left. (B) Western blot analysis of Huh7.5.1 cells transfected
with JFH 5a-GFP or its derivative RNAs containing adaptive mutations. Protein levels were analyzed by western blotting with anti-NS5a, anti-core or
anti-GAPDH antibodies, respectively. (C) Huh7.5.1 cells were infected with JFH 5a-GFP, Ad 9, JFH-G m1, JFH-G m2, JFH-G m3, JFH-G m4 or JFH-G m5
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mutation (compare columns JFH-R m3 and JFH-R m4 with
columns JFH 5a-Rluc and JFH-R m2 in Fig. 4D), consistent with
the result shown in Figure 4C. Importantly, the ratios of
intracellular to extracellular infectious virions were approximately
the same for all viruses (Fig. 4E), indicating that the p7 mutation
does not affect viral release. Collectively, the results presented in
Figure 4 support the conclusion that the adaptive mutation in the
p7 protein facilitates an earlier stage of virus production, such as
virus assembly and/or morphogenesis.
Viral infectivity of JFH-R m2 was increased about 7-fold when
we collected the culture supernatant at 5 days after transfection
with 5 days accumulation (Fig. 4B). However, viral infectivity of
JFH-R m2 was similar to wild type virus when we collected the
culture supernatants at 2 days after transfection with 2 day virus
accumulation (Fig. 4C). Based on these findings, we made
hypothesis that mutation in E2 protein increased the viability of
HCV in culture supernatant at 37uC. To examine the effect of the
adaptive mutation in E2 protein on the viability of the
extracellular virion in culture media, we incubated the same
infectious dose of JFH, JFHm2, JFH-m3 and JFH-m4 viruses at
4uCo r3 7 uC for the times indicated in Figure 5A and 5B, and
measured their infectivity. Except for a slight, but insignificant,
reduction in the infectivity of viral stocks stored at 4uC for
48 hours, there was no significant difference in infectivity among
the four viruses after incubation at 4uC for 48 hours (Fig. 5A).
However, differences in virus viability at 4uC among the mutant
viruses were observed when viruses were incubated at 4uCu pt o3
weeks (Fig. S2B). The half life of the wild type virus was about 2
weeks at 4uC as reported by Ciesek et al. [21]. Viability of the E2
mutant was higher than that of wild type virus even at 4uC (Fig.
S2B). The p7 mutation also weakly contributed to the virus
viability even though the extent of stabilization was smaller than
the E2 mutation (Fig. S2B). The viability of virions decreased
dramatically after incubation of viral stocks at 37uC (Fig. 5B). This
decrease was greatest for wild-type and JFH-m3 viruses, which
both had a half-life of 2.5 to 3 hours at 37uC (Fig. 5B). In contrast,
the half-life of JFH-m2 and JFH-m4 viruses was 5 to 6 hours at
37uC (Fig. 5B), suggesting that the mutation in the E2 protein
generated by the culture system increases virion viability at 37uC.
Interestingly, the viability of infectious JFH virus without the
adaptive E2 mutation in the cell culture system (2.5 to 3 hours)
was similar to that of HCV particles in infected patients
(,3 hours) [22,23].
In order to understand the molecular basis of the increased
viabilityoftheE2mutant virus at37uC, weinvestigated whetherthe
E2 mutant has acquired prolonged capability of interaction with the
best known HCV receptor protein CD81 at 37uC. For this purpose,
we generated a recombinant fusion protein (CD81-Fc) containing
the Fc region of human IgG and the large extracellular loop (LEL)
of human CD81 that is responsible for the interaction with HCVE2
[24]. After incubation of the same infectious dose of JFH, JFH-m2,
JFH-m3, and JFH-m4 viruses at 37uC for the times indicated in
Figure 5C, virion particles were precipitated by a protein G agarose
resin conjugated with the CD81-Fc fusion protein (CD81-Fc-
conjugated resin). The amounts of viral RNAs precipitated by the
CD81-Fc-conjugated resin were determined by quantitative RT-
PCR. The ratios of bound RNAs to total RNAs wereapproximately
the same among the wild type and mutant viruses before incubation
at 37uC (Fig. S3). The virion particles associated with the CD81-Fc-
conjugated resin and the HCV RNA entered into Huh7.5.1 after
infection was drastically reduced by the incubation of virus stocks at
37uC (Fig. 5C and Fig. S4). This indicates that the amounts of
virions which can interact with the viral receptor CD81 decrease
dramatically by the incubation of the viral stock stocks at 37uC. In
other words, the E2 proteins on the virus envelopes are inactivated
veryrapidlyat37uC.Thereducingrateoftheresin-bound virionsat
37uC differs greatly among the mutant viruses. The viruses with the
mutation in the E2 protein (JFH-m2 and JFH-m4) showed higher
sustainment of CD81-binding capability at 37uC than the viruses
containing wild-type E2 (JFH and JFH-m3) (Fig. 5C). We analyzed
therelationship between the CD81-bindingcapabilityofvirusesand
the infectivity of the viruses Fig. 5D). A linear correlation was
observed between the CD81-binding capability and the infectivity
of viruses (R
2=0.8834). The linear relationship between the CD81-
binding capability and the virus infectivity was also observed from
individual wild-type and mutant viruses (Fig. S5). The data
collectively indicate that the E2 protein is unstable at the
physiological temperature, and incubation of viruses at 37uC results
in loss of the CD81-binding capability of E2. The mutation in the
E2 prolongs the CD81-binding capability of E2 protein resulting in
higher infectivity of the mutant viruses JFH-m2 and JFH-m4. It is
noteworthy that the mutation in the p7 also partially increases
viability of virion particles at 37uC even though the effect is not as
strong as the E2 mutation (Fig. 5).
To examine the possibility that the adaptive mutations in E2 and
p7 influence the level and processing of the E2-p7-NS2, we pulse-
labeled proteins in Huh7.5.1 cells transfected with JFH 5a-GFP,
JFH-G m2, JFH-G m3, or JFH-G m4 RNAs. Immunoprecipitation
of viral proteins with an E2-specific monoclonal antibody (AP33)
revealed no significant differences in the amounts of mature E2/
E2p7 proteinor unprocessed E2-p7-NS2 protein among the various
mutants (Fig. 6). Therefore, the adaptive mutations do not affect the
level or processing of E2, p7 or NS2 proteins.
In order to test the usefulness of the cell culture-adapted virus in
developing anti-viral agents against HCV, we tested effects of anti-
HCV agents [interferon-alpha and BILN2061 (a protease
inhibitor)] on wild type HCV (JFH 5a-Rluc) and the mutant virus
(JFH-R m4) containing the E2/p7 double mutation (Fig. S6).
Proliferation of the mutant virus (JFH-R m4) decreased dramat-
ically in dose dependent manners by the anti-HCV agent
treatments similarly to JFH 5a-Rluc containing wild type E2 and
p7 proteins (Fig. S6). This clearly demonstrates that the virus with
the adaptive mutations (JFH-R m4) is useful for screening and
testing anti-HCV effects of various agents.
Discussion
In this study, we developed an efficient HCV cultivation system
by selecting for HCVs with cell culture-adaptive mutations. The
adaptive mutations increased the infectious viral titer by about
100-fold (Fig. 3D) without affecting the expression of viral protein
or viral RNA replication (Fig. 3B and 4A). Two mutations, one
located in E2 and one in p7, were responsible for enhanced virus
infection, with each increasing viral infectivity at different stages of
the HCV life cycle.
The T563I mutation located in the E2 protein enhanced virus
infectivity by increasing the viability of the virion in culture media
at 37uC (Fig. 5B). To our knowledge, this is the first report
describing a mutation that increases virion’s viability in culture
viruses, and the NS5a-GFP signal was visualized by fluorescence microscopy (green). (D) Viral titers were determined using a TCID50 assay. The bars
and lines represent the means and standard deviations, respectively, from three independent experiments.
doi:10.1371/journal.pone.0022808.g003
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PLoS ONE | www.plosone.org 6 August 2011 | Volume 6 | Issue 8 | e22808Figure 4. A mutation in the p7 protein augmented a virion assembly step. (A) Replication of JFH 5a-Rluc, JFH-R m2, JFH-R m3 and JFH-R m4
RNAs was investigated using a luciferase reporter assay. Cells were transfected with RNAs and harvested at the indicated times. Luciferase activity
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G451R mutation in the E2 protein that increased infectivity titer
by 10-fold, identified by Zhong et. al, has a selective advantage at
the entry stage of virus [25], and an N534K mutation in E2
protein identified by Delgrange et. al, facilitates the infection of
JFH virus [26]. In this latter study, the authors suggested that the
higher infectivity of the N534K mutant virus was attributable to a
change in the glycosylation status of the E2 protein.
The E2 protein is an envelope protein that is exposed on the
surface of a virion particle and recognizes viral receptor protein(s),
suchasCD81,on thesurfaceofhostcells.Interestingly,the mutation
in the E2 protein (T563I), which results in prolonged CD81-binding
capacity of E2 at 37uC (Fig 5C), is closely located to the CD81-
binding site according to the recent paper describing the tertiary
organization of HCV E2 ectodomain [27]. Therefore, it is plausible
thatthe E2mutationmayincreasethe heatstabilityofthe E2protein
by augmenting the maintenance of E2 conformation which allows
the binding of CD81. This prolonged binding capability of E2
protein with CD81 results in higher infectivity of the mutant virus at
the physiological temperature (Figures 5B and 5C).
The high turnover rates of HCV are very likely contribute to the
rapid generation of viral diversity and the viral escape from the
host immune surveillance and antiviral therapy. This may be one
of the reasons of the frequent development chronic hepatitis by
HCV infection. Nevertheless, HCVs with longer half lives are
generated in vivo, which were revealed by the observation of
various HCVs having different half-lives from HCV patients [22].
Two functions of the p7 protein in HCV proliferation have been
suggested based on earlier studies on p7 and other structurally
similar viral proteins. P7 is considered to be a member of the
viroporins, similar to 6k of alpha-viruses, M2 of influenza virus A
and Vpu of HIV-1 [28]. Indeed, the p7 protein has been shown to
have ion channel activity in artificial lipid membranes
[12,29,30,31]. One untested possibility is that the p7 N765D
mutation changes the activity of the ion channel, resulting in
increased infectivity of the virus. Alternatively, p7 may facilitate
virus production by interacting with other viral proteins, similar to
the M2 protein of influenza virus, which facilitates virus
production through an interaction with M1 [32]. Previous studies
have reported that p7 interacts with other viral proteins and
suggested that these interactions are essential for virus production
[14,33,34]. For instance, p7 has been shown to play an important
role in virus assembly [35]. In this context, a mutation in the p7
protein has been reported to compensate for virus assembly defects
that arise due to mutations in the core protein [34]. Moreover,
using an intergenotypic chimeric HCV cultivation system, it has
been shown that two compensatory mutations in p7 and NS2
proteins play a key role in the assembly and release of infectious
virus, and that the interaction between p7 and NS2 proteins are
essential for this process [33].
A number of observations reported here also support the
conclusion that the N765D mutation in the p7 protein increases
virus production by enhancing viral assembly and/or morphogen-
esis steps. First, time-dependent replication levels are very similar
among wild type and m2, m3 and m4 mutations (Fig. 4A). Second,
the time required for virus release from viral infection is shorter in
m3 and m4 mutants (Fig. 4C). Finally, the ratio of infectious virion
particles in the media to that inside the cells is similar among wild
type and m2, m3 and m4 mutations (Fig. 4E). Therefore, the
N765D mutation may augment virus production by modulating the
interaction(s) with other viral proteins involved in virion production,
such as the core and NS2. This N765D mutation has been observed
in other JFH variants adapted to Huh7.5.1 cells. For instance, Kaul
and co-workers found that the same mutation in p7 was included
among the cell culture-adapted mutations that increased infectivity
of HCV [14,15]. Recently, Russell et. al also suggested that N765D
facilitates viral assembly and/or morphogenesis [35].
Interestingly, different patterns of virus distribution were
observed in cells infected by JFH-G m2 and JFH-G m3 viruses
(panel d and e in Fig. 3C). The JFH-G m2 virus containing a
mutation in the E2 protein showed a widely dispersed infection
pattern, with the presence of many foci. In contrast, the JFH-G
m3 virus containing a mutation in the p7 protein was distributed
in a sporadic but focused infection pattern; these cells had fewer
foci, and a number of cells had a single focus of infection. This
difference may be attributable to the characteristics of the
individual mutations. The JFH-G m2 virus, containing a
mutation in the E2 protein that increased viability, may be able
to travel over greater distances than wild-type virus before it is
inactivated, resulting in a more dispersed infection pattern. JFH-
G m3 virus, which has a mutation in p7 that facilitates faster virus
production, may yield fewer, larger foci. The JFH-G m4 virus
containing both mutations acquired these two advantages and
showed that maximal infectivity, reflecting a synergistic effect of
two mutations.
One mutation in the E1 protein (H316R) had a negative effect
on viral infectivity (Fig. 3D). Nakai et. al showed that four amino
acids (residues 312–315) of the E1 protein are crucial for
interacting with the assembled core proteins [36], and four more
(residues 316–319) were partially involved. Therefore, it is likely
that the H316R mutation hampers virus production by inhibiting
the interaction between E1 and assembled HCV core proteins.
Recently, Han et al. found mutations in the nonstructural
proteins NS3 and NS5a enhancing the production of HCV
containing GFP gene similarly to the JFH 5a-GFP virus [37]. It
would be a desirable experiment to test whether the mutations in
E2 and p7 described in this paper have a synergistic effect with the
mutations in NS3 and NS5a.
In summary, we have developed an efficient HCV cultivation
system through continuous culture of JFH containing a reporter
values are expressed relative to reporter activity measured at 4 hours (reference value=1). The bars and lines represent the means and standard
deviations, respectively, from three independent experiments. (B) Infectivity of culture fluids harvested 5 days after transfection with JFH 5a-Rluc, JFH-
R m2, JFH-R m3 or JFH-R m4 RNAs was determined by measuring luciferase activity in cells 3 days after inoculation of Huh7.5.1 cells. Luciferase
activity values are expressed relative to reporter activity measured in cells infected with the JFH 5a-Rluc virus (reference value=1). The bars and lines
represent the means and standard deviations, respectively, from three independent experiments. (C) The kinetics of virus release into the media of
transfected cells in panel A were measured. Culture supernatants were harvested at the indicated times and used to inoculate Huh7.5.1 cells. Three
days after infection, luciferase activity in cells was measured and normalized to protein concentration, determined by the Bradford assay. The bars
and lines represent the means and standard deviations, respectively, from three independent experiments. (D) Two days after transfection, culture
media were harvested to collect extracellular virus. Virus-producing cells were washed and lysed by four freeze-thaw cycles to release intracellular
virus. Infectious virus titers in the media and inside the cells were investigated by infecting Huh7.5.1 cells with media and cell lysates, respectively.
The extracellular (white bars) and intracellular (gray bars) viral titers were measured by luciferase assay. The relative ratios of intracellular and
extracellular infectious viruses are shown in panel (E). The bars and lines represent the means and standard deviations, respectively, from three
independent experiments.
doi:10.1371/journal.pone.0022808.g004
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e22808Figure 5. A mutation in the E2 protein increased virion viability at 376C. (A and B) Infectious viral titers remaining in the media were
determined by infecting Huh-7.5.1cells after same amount of JFH, JFH-m2, JFH-m3 and JFH-m4 viruses were incubated at 4uC (A) or 37uC (B) for the
indicated times. Viral titers were determined by counting numbers of plaques visualized by an immune-fluorescence method. (C) The same infectious
dose of JFH, JFH-m2, JFH-m3, and JFH-m4 viruses were incubated at 37uC for the indicated times, and then CD81-interacting viruses were
precipitated by a protein G agarose resin conjugated with CD81-Fc fusion protein. The amounts of resin-bound virions were measured by
quantitative RT-PCR. The relative amount of resin-bound viruses is depicted. The dots and lines represent the means and standard deviations,
respectively, from three independent experiments. (D) The relationship between CD81-binding capability and infectivity of HCV viruses. The
relationship between CD81-binding capability and infectivity of the mutant viruses were analyzed by plotting the relative CD81-binding capabilityo f
various viral stocks in panel (C) on the x-axis and relative viral titers of the stocks in panel (B) on the y-axis. The correlation co-efficient was calculated
using sigma plot.
doi:10.1371/journal.pone.0022808.g005
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mutations selected during culture was approximately 100-fold
higher than that of the original JFH 5a-GFP virus. Various
reporters, including a luciferase gene, could be incorporated at the
GFP site without reducing viral infectivity. This system will be
useful for investigating the viral life cycle and developing new anti-
HCV drugs and vaccines.
Materials and Methods
Plasmid construction
The pJFH 5a-GFP and pJFH 5a-Rluc plasmids have been
described previously [20]. A pJFH 5a-GFP plasmid containing
adaptive mutations was constructed by amplifying the structural
region encoding the core to NS2 using RT-PCR (Fig. 1B). One
microgram of total RNA and a primer designated csp 426 (59-
CCG AGA GCA CAC AGC TG-39) were mixed, heated at 65uC
for 10 min, cooled, and then reverse transcribed with Expand RT
(Roche Biochemicals) according to manufacturer’s instructions.
Long-distance PCR was performed using Expand Long template
PCR system (Roche Biochemicals) and the primers csp 423 (59-
GCC TAG CCA TGG CGT TAG-39) and csp 427 (59-TCG
GAA GAG CCC AAC GAC-39). The amplified DNA fragment
was digested with Age I and Avr II and inserted into the parental
pJFH 5a-GFP. Of the twelve independent clones obtained, three,
designated Ad 9, Ad 12 and Ad 16, were found to have RNA
transcripts that expressed viral proteins. To construct GFP-
containing mutant constructs, Ad 9 was digested with AgeI and
BsiWI (pJFH-G m1), BsiWI and KpnI (pJFH-G m4), KpnI and
AvrII (pJFH-G m5) or Asc I (pJFH-G m2 and pJFH-G m3), and
the resulting fragments were inserted into pJFH 5a-GFP. To
construct Rluc-containing mutant variants of m2, m3 and m4
(pJFH-R m2, pJFH-R m3 and pJFH-R m4, respectively), the
corresponding pJFH-GFP mutant constructs were digested with
AgeI and AvrII and inserted into pJFH 5a-Rluc.
Antibodies
Antibodies against the core and NS5a used in western blotting
were gifts from Ralf Bartenschlager (University of Heidelberg).
The anti-core and anti-NS5a antibodies used in immunofluores-
cence applications were from Affinity Bioreagents and Austral
Biologicals, respectively. The antibody against E2 (AP 33) was a
gift from Arvind Patel (University of Glasgow) [38]. The antibody
against GAPDH was purchased from AbD SeroTec.
Cell culture and TCID50 assay. Huh7.5.1 cells [1] were
grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco)
supplemented with antibiotics (100 U/ml penicillin; 10 mg/ml
streptomycin) and 10% fetal bovine serum (Sigma) at 37uCi na
humidified 6.0% CO2 environment. The infectivity of luciferase
reporter-containing HCV was determined as previously described
[20]. The tissue culture 50% infectivity dose (TCID50) was
calculated based on previously described methods [17]. Briefly,
Huh7.5.1 cells were plated into 96 well at 5610
3 cells per well.
Culture supernatants were serially diluted 10-fold in normal growth
media. 8 wells per dilution were infected. 3 days after infection,
whole plates were investigated using fluorescence microscope. Wells
containing GFP positive cells were counted as positive and TCID50
was determined using the number of these positive wells.
Fluorescence Microscopy
Fluorescence microscopy was performed as described previously
[20,39].
Luciferase assay
Luciferase assays were performed using a luciferase assay kit
(Promega) according to manufacturer’s instructions, as described
previously [40].
RNA transcription and RNA electroporation
In vitro transcription and RNA electroporation were performed
as described previously [18].
Figure 6. Processing of the E2-P7-NS2 polypeptides of JFH 5a-GFP, JFH-G m2, JFH-G m3 and JFH-G m4 viruses. Huh7.5.1 cells were
transfected with the indicated RNAs and then incubated for 48 hours. Newly synthesized proteins were labeled with [
35S]methionine/cysteine for
24 hours and then chased with unlabeled media for 0, 3 or 6 hours. Mock-transfected cells were used as a negative control. The labeled cell lysates
were immunoprecipitated using an E2 specific antibody (AP33). Immunocomplexes were resolved by SDS-PAGE and E2-related proteins were
visualized by autoradiography. HCV proteins are indicated by arrowheads on the left, and the positions of the molecular weight markers are given on
the right. The relative amounts of E2/E2p7, which were normalized to those in starting time point (t0), are depicted below the figure.
doi:10.1371/journal.pone.0022808.g006
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freeze-thawing
Cell culture supernatants from JFH RNA-transfected Huh7.5.1
cells were harvested and cells were washed three times with PBS,
scraped and centrifuged for 2 min at 10006g. Cell pellets were
resuspended in a volume of DMEM/10% FBS equivalent to the
volume of harvested culture supernatants and subjected to four
freeze-thaw cycles using liquid nitrogen and a heating block set to
37uC. Lysates were centrifuged at 10006g for 2 min to remove
cell debris and passed through a 0.45 mm filter.
Metabolic radiolabeling of proteins and
immunoprecipitation
Metabolic radiolabeling of proteins and immunoprecipitation
were performed as described previously [15].
Determination of viability of viruses
The titers of JFH, JFH-m2, JFH-m3 and JFH-m4 viruses were
determined by counting plaques visualized by a immune-
fluorescence method using Huh7.5.1 cells [18]. Viral stocks were
serially diluted in DMEM-10% FBS and inoculated on Huh7.5.1
cells. The HCV-infected cells were cultivated for 72 hours, and
then plaques were visualized by an antibody against HCV core.
The viral titers were measured three times, and mean value and
standard deviation are depicted in the graphs.
CD81 interaction assay
The CD81-Fc fusion protein and IgG-Fc protein were
e x p r e s s e di n2 9 3Tc e l l sa n dt h e np u r i f i e db yu s i n gp r o t e i nG
agarose beads. The purified CD81-Fc proteins (12.5 mg) were
conjugated with protein G agarose resin by incubating them
together at 4uC for 4 hours. The viral stocks of JFH, JFH-m2,
JFH-m3, and JFH-m4 were incubated with CD81-Fc-conju-
gated resin at 4uC over night. The resins were suspended in
300 ml PBS, and then the resin-bound viral RNAs were
extracted using TRIzol LS (Invitrogen). The amounts of
resin-bound virions were measured by quantitative RT-PCR
using primers HCV RT F(59-TGA GGA ACT ACT GTC TTC
ACG-39)a n dH C VR TR ( 5 9-ATC AGG CAG TAC CAC AAG
GC-39).
Supporting Information
Figure S1 Mutations in E2 and p7 proteins increased
viral infectivity. Huh7.5.1 cells were infected with JFH, JFH
m-2, JFH m-3, or JFH m-4 viruses containing same mutations as
JFH 5a-GFP, JFH-G m1, JFH-G m2, JFH-G m3, JFH-G m4 or
JFH-G m5 viruses, respectively. However, these viruses do not
contain a reporter gene (GFP). Viral titers were determined using
a TCID50 assay. The bars and lines represent the means and
standard deviations, respectively, from three independent exper-
iments.
(TIF)
Figure S2 Thermal effects on viabilities of viruses
containing mutations in E2 and p7. The amounts of
infectious viruses remaining in the media after thermal treatments
[incubation at 4uC (A and B), 37uC (C), or room temperature (D)
for the indicated times] were determined by measuring luciferase
activities after infecting Huh-7.5.1 cells with JFH 5a-Rluc, JFH-R
m2, JFH-R m3 and JFH-R m4 viruses. The relative viral
infectivity at each time point is depicted after normalization to
the viral infectivity before the thermal treatments that is set to 1.
The bars and lines represent the means and standard deviations,
respectively, from three independent experiments.
(TIF)
Figure S3 Proportion of HCV viruses precipitated by a
CD81-Fc-conjugated resin. The amounts of total viral RNAs
from same infectious dose of JFH, JFH-m2, JFH-m3, and JFH-m4
viruses (Total) and viral RNAs bound to a CD81Fc resin (IP with
CD81Fc) were measured by quantitative RT-PCR. The copy
numbers of HCV RNAs (A) and the ratios of bound to total viral
RNAs (B) are depicted. The bars and lines represent the means
and standard deviations, respectively, from three independent
experiments. The ratios of bound to total RNAs were approxi-
mately the same among the wild type and mutant viruses.
(TIF)
Figure S4 Measurement of virus entry. (A) The same
infectious dose of JFH, JFH-m2, JFH-m3, and JFH-m4 viruses
were incubated at 37uC for the indicated times, and then
incubated with Huh7.5.1 cells for 3 hours. The HCV-infected
cells were washed five times with PBS, and RNAs in the cells were
isolated. The amounts of viral RNAs in the cells were measured by
quantitative RT-PCR. The relative amounts of viral RNAs are
depicted. The dots and lines represent the means and standard
deviations, respectively, from three independent experiments. (B)
The relationship between CD81-binding capability and the entry
of viruses. The relationship between CD81-binding capability and
the entry of viruses was analyzed by plotting the relative CD81-
binding capability of viruses in Figure 5C on the x-axis and
relative entry of the viruses in panel (A) on the y-axis. The
correlation co-efficient was calculated using sigma plot.
(TIF)
Figure S5 The relationship between CD81-binding
capability and infectivity of individual HCV virus. The
relationship between CD81-binding capability and infectivity of
wild-type or individual mutant virus was analyzed by plotting the
relative CD81-binding capability of a specific viral stock in
Figure 5C on the x-axis and relative viral titer of the stock in
Figure 5B on the y-axis. The correlation co-efficient was calculated
using sigma plot.
(TIF)
Figure S6 The effects of antiviral agents on cell culture-
adapted virus. Huh7.5.1 cells were infected with JFH 5a-Rluc
virus or JFH-R m4 and then treated with the indicated
concentration of BILN 2061 (A) or interferon-alpha (B) for 3
days. Cells were harvested, and luciferase activities in the cells
reflecting the amounts of viruses were measured at 3 days post
infection. The relative amounts of viruses are depicted by setting
the luciferase activity in mock-treated cells to 1. The dots and lines
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